Gene
TOP2A
TOP2A is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (40), Actionable biomarkers (1), Trial mentions (4), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention TOP2A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
TOP2A has 4 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 17 of 11,460 | 0.15% |
| 2022 | 0 of 8,285 | 0.00% | 24 of 13,598 | 0.18% |
| 2021 | 0 of 8,692 | 0.00% | 25 of 15,045 | 0.17% |
| 2020 | 0 of 7,640 | 0.00% | 32 of 14,459 | 0.22% |
| 2019 | 0 of 7,300 | 0.00% | 19 of 12,159 | 0.16% |
| 2018 | 0 of 6,927 | 0.00% | 16 of 11,854 | 0.13% |
| 2017 | 0 of 6,558 | 0.00% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (40)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Cepheid | Diagnostic provider | Clinical validationAnalytical validation | 2 | March 01, 2022 |
| Danaher Corp | Context dependent | Clinical validation | 1 | March 01, 2022 |
| Affymetrix | Reagent supplier | Clinical validationAnalytical validation | 3 | November 01, 2020 +1 undated |
| NanoString Technologies | Unclassified | Clinical validation | 1 | November 01, 2020 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 3 | November 01, 2020 +2 undated |
Showing 5 of 40 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| TOP2A amplification | Anthracyclines | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (4)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02506361 | Trial eligibility (AACT) |
| NCT00689156 | Trial eligibility (AACT) |
| NCT00493870 | Trial outcomes (AACT) |
| NCT00493649 | Trial outcomes (AACT) |
Target-disease associations (291)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Clinical precedence |
| Acute hepatic failure | phenotype | Expression Atlas |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| BMI-adjusted hip circumference | measurement | GWAS credible sets |
| Benign Smooth Muscle Neoplasm | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 291 associations.
Vendor sourcing (23)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2908G>T (p.V970L) alteration is located in exon 23 (coding exon 23) of the TOP2A gene. This alteration results from a G to T substitution at nucleotide... | View ClinVar record SCV003540830.3 |
| Children's Hospital of Philadelphia | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000296991.3 |
| Dako | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Signed informed consent 2. Histologically confirmed invasive breast carcinoma which has been micro-radical removed by breast preserving surgery or mast... | View trial NCT00689156 |
| Dako | Trial collaborator | Mentioned in trial textTrial free-text mention | TOP2A | View trial NCT00689156 |
| Danish Breast Cancer Cooperative Group | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Signed informed consent 2. Histologically confirmed invasive breast carcinoma which has been micro-radical removed by breast preserving surgery or mast... | View trial NCT00689156 |
Showing 5 of 23 sourcing records.
Trial-cited literature (317)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b. | Cardio-oncology (London, England) | 2025 | 4 |
| Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 4 |
| Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal transduction and targeted therapy | 2025 | 2 |
| Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial. | Cancer communications (London, England) | 2025 | 2 |
| Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | The Journal of clinical investigation | 2024 | 47 |
Showing 5 of 317 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D1017V | 1 | 2015 | PMID 25741868 |
| p.D179Y | 1 | 2014 | PMID 24576155 |
Literature-extracted relations (72)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anthracyclines | Chemical | associate |
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial. | 2025 |
| DOXORUBICIN | Chemical | associate |
Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b. | 2025 |
| Anthracyclines | Chemical | associate |
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. | 2024 |
| DOCETAXEL | Chemical | associate |
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. | 2024 |
| TRASTUZUMAB | Chemical | associate |
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. | 2024 |
Showing 5 of 72 relation assertions.
Organizations publishing (296)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 13 | 1999 to 2023 |
| Moffitt Cancer Center | Hospital | 9 | 2008 to 2023 |
| The University of Texas System | Academic | 9 | 2015 to 2023 |
| University of London | Academic | 9 | 2011 to 2024 |
| Dana-Farber Cancer Institute | Other | 7 | 2011 to 2022 |
Showing 5 of 296 organizations.
Where TOP2A appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
233 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.